Published date: 24 October 2023
Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.
Contract summary
Industry
Health services - 85100000
Location of contract
England
Value of contract
£1,400,000 to £2,100,000
Procurement reference
CF-1958800D0O000000rwimUAA
Published date
24 October 2023
Closing date
24 November 2023
Closing time
12pm
Contract start date
3 January 2024
Contract end date
31 March 2025
Contract type
Service contract
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the National Institute of Health Research (NIHR) and Genomics England (GEL), with the aim to facilitate access to personalised cancer vaccine research trials. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister. See link (https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials#:~:text=It will work by creating,become part of standard care)
Through the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial.
The CVLP is company agnostic and is being set up in a phased approach with a small number of Trusts to test the pathway from September 2023. For the first phase, the CVLP is supporting one cancer vaccine clinical trial. It is likely that three to four additional trials will be brought into the CVLP during 2024.
NHS England is looking for a supplier to provide the digital infrastructure and clinical liaison function to manage the end-to-end pathway of the CVLP for up to 2000 patients until March 2025.
Initial term is 15 months to a maximum value of £1,400,000. There is provision for a potential 12 month extension up to a maximum value £700k but this is subject to approvals by NHSE.
More information
Additional text
-
To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome.
Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at:
Phone: 0800 9956035
E-mail: support-health@atamis.co.uk
About the buyer
Contact name
NHSE Commercial
Address
Quarry Hill
Leeds
LS2 7UE
GB
Share this notice
Closing: 24 November 2023, 12pm
All content is available under the
